相关实验视频
Updated: Jul 12, 2025

06:00
Fixation and Operational Method for Abdominal Massage in T2DM Mice
Published on: March 7, 2025
232
甲福明抑制了消化蛋白酶,并损害了小鼠的蛋白质消化
Caleb J Kelly1, Andrew A Verdegaal2, Brent W Anderson2
1Microbial Sciences Institute, Yale University, West Haven, Connecticut, USA; Section of Digestive Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
The Journal of biological chemistry
|October 20, 2023
概括
甲福明是一种常见的2型糖尿病药物,可以通过抑制肠酶等消化酶引起胃肠道问题. 这导致肠道中蛋白质消化受损,这可能解释了常见的副作用.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 甲胺是一种广泛处方的第一线治疗2型糖尿病的药物.
- 胃肠道 (GI) 副作用与甲福明是常见的,可以限制剂量.
- 高肠道药物度的发生是由于每日大剂量的吸收不良.
研究的目的:
- 为了研究甲福明对胃肠道中消化酶活性的影响.
- 为了确定甲福明是否抑制参与蛋白质消化的关键酶.
- 探索甲福尔酶抑制及其胃肠道副作用之间的潜在联系.
主要方法:
- 在体外评估甲福明对肠酶和其他消化酶的影响.
- 用甲福明治疗小鼠胃肠组织以测量酶活性.
- 在小鼠体内研究以评估肠酶和素活性,以及肠膜中的蛋白质消化.
主要成果:
- 发现甲胺在人类十二指肠中发现的度下抑制了肠酶和其他消化酶.
- 甲福明治疗减少了小鼠胃肠组织中的肠酶活性.
- 接受甲胺治疗的小鼠显示肠内酶和素活性下降,蛋白质消化功能受损.
结论:
- 甲胺抑制了关键的消化酶,包括肠酶.
- 甲胺诱导的肠道蛋白质消化不良是一种潜在的机制,有助于其胃肠道副作用.
- 这些发现为甲福明对营养吸收和整体药物耐受性的影响提供了新的见解.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
184
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
184
Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192
Oral Hypoglycemic Agents: Biguanides and Glitazones
212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Protein Digestion
103.8K
Protein digestion begins in the stomach, where the highly acidic environment can easily disrupt protein structure by exposing the peptide bonds of polypeptide chains. After polypeptide chains are broken into individual amino acids by a series of digestive enzymes, the amino acids are transported to the liver via the bloodstream to produce energy.
103.8K
Overview of Protein Metabolism
1.3K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
1.3K

